Tahoe Therapeutics – a biotech start-up based mostly in San Francisco, California – is creating the most important ever atlas of cell-chemical interactions to tell drug discovery. Combining automated pipetting techniques from INTEGRA Biosciences, Parse Biosciences’ Evercode™ single-cell RNA sequencing (scRNA-seq) merchandise, and its personal proprietary AI algorithms, the corporate already has a number of drug discovery packages working in parallel throughout a number of most cancers varieties, and is increasing into different therapeutic areas.
Workflow automation is crucial for the Tahoe Therapeutics group’s intention of producing among the largest scRNA-seq datasets on the earth. The corporate invested in an ASSIST PLUS pipetting robotic and VIAFLO handheld digital pipette to automate its analysis workflows. INTEGRA’s partnership with Parse Biosciences means these instruments work seamlessly with the Evercode merchandise to offer a validated, turnkey resolution protecting each stage of scRNA-seq pattern preparation. These instruments allow the corporate to scale up its operations whereas bettering reliability and decreasing hands-on time by as much as 75 %.
The corporate goals to make use of the pace and accuracy of those automated techniques to generate a dataset fifty instances bigger than its already record-breaking Tahoe 100 million single-cell atlas.
We rapidly realized that, as we had been producing an increasing number of knowledge and pushing the boundaries of the sphere, we had been lacking robotic and excessive throughput options. Automation with the ASSIST PLUS has elevated our throughput for single-cell preparation greater than 5-fold. A very powerful factor is that it is extremely correct: you are not counting on the inherent variability of guide processing. The mix of INTEGRA’s devices and Parse Biosciences’ kits permits us to leapfrog many biopharmaceutical firms and generate bigger datasets utilizing much less instrumentation, reagents and capital.”
Johnny Yu, Co-founder and Chief Scientific Officer, Tahoe Therapeutics